Managing What Matters: Practical Adverse Event Management Skills for Hormone Receptor-Positive Breast Cancer Therapies

This activity was originally presented at the 2026 Breast Cancer Day of Education.

In collaboration with HOPA, COA, & Oncology State Societies.

Program Description

Adverse event (AE) management has become a critical rate-limiting step preventing patients from receiving the full benefit of therapy for hormone receptor-positive (HR+)/HER2– breast cancer, particularly as patients are exposed to multiple lines of targeted agents and complex oral regimens over time. Across therapeutic classes such as CDK4/6 inhibitors, PI3K/AKT inhibitors, and antibody-drug conjugates, predictable toxicities including gastrointestinal events, cytopenias, QTc changes, metabolic complications, and organ-specific effects can drive dose reductions, unplanned holds, or permanent discontinuation if not anticipated and managed proactively. This session will examine approaches to standardize proactive monitoring across drug classes and to improve pharmacist involvement in developing safety protocols so that AEs are addressed early, consistently, and in a way that preserves long-term treatment benefit. Participants will engage in rapid-fire clinical scenarios followed by expert-led small-group discussion to facilitate development of practical tools for workflows that participants may apply within their own practice settings to support continued use and mitigate AEs associated with advanced therapies for patients with HR+/HER2– breast cancer.

Target audience: Oncology pharmacists
Type of activity: Application
Release date: July 30, 2026
Expiration date: July 30, 2027
Learner level: Intermediate, Advanced
Time to complete activity: 1.25 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify proactive, pharmacist-led strategies to anticipate, prevent, and mitigate common adverse events (AEs) associated with hormone receptor-positive (HR+) breast cancer therapies across treatment classes
• Explore risk factors and monitoring strategies for high-impact AEs associated with HR+ breast cancer therapies, including CDK4/6 inhibitors, PI3K/AKT inhibitors, oral selective estrogen receptor degraders, PARP inhibitors, and antibody-drug conjugates
• Apply collaborative, pharmacist-driven approaches to manage therapy-related metabolic toxicities, including coordination with oncology, endocrinology, and primary care teams
• Use patient-centered counseling strategies to support adherence, persistence, and shared decision-making in the setting of chronic or cumulative AEs from HR+ breast cancer therapies

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.25 contact hours (0.125 CEU) under the ACPE universal activity number 0290-0000-26-243-H01-P. The activity is available for CE credit through July 30, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Jordan Hill, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Kylie Ferrentino; and Brianna Winters.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms